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BACKGROUND: To examine the association between the degree of risk 
factor control and cardiovascular disease (CVD) risk in type 2 diabetes 
and to assess if the presence of cardio-renal disease modifies these 
relationships.
METHODS: A retrospective cohort study using data from English 
practices from CPRD GOLD (Clinical Practice Research Datalink) and the 
SCI-Diabetes dataset (Scottish Care Information-Diabetes), with linkage to 
hospital and mortality data. We identified 101 749 with type 2 diabetes 
(T2D) in CPRD matched with 378 938 controls without diabetes and 
330 892 with type 2 diabetes in SCI-Diabetes between 2006 and 2015. 
The main exposure was number of optimized risk factors: nonsmoker, 
total cholesterol ≤4 mmol/L, triglycerides ≤1.7 mmol/L, glycated 
haemoglobin (HbA1c) ≤53 mmol/mol (≤7.0%), systolic blood pressure 
<140mm Hg, or <130 mm Hg if high risk. Cox models were used to assess 
cardiovascular risk associated with levels of risk factor control.
RESULTS: In CPRD, the mean baseline age in T2D was 63 years and 
28% had cardio-renal disease (SCI-Diabetes: 62 years; 35% cardio-
renal disease). Over 3 years follow-up (SCI-Diabetes: 6 years), CVD 
events occurred among 27 900 (27%) CPRD-T2D, 101 362 (31%) SCI-
Diabetes-T2D, and 75 520 (19%) CPRD-controls. In CPRD, compared with 
controls, T2D participants with optimal risk factor control (all risk factors 
controlled) had a higher risk of CVD events (adjusted hazard ratio, 1.21; 
95% confidence interval, 1.12–1.29). In T2D participants from CPRD 
and SCI-Diabetes, pooled hazard ratios for CVD associated with 5 risk 
factors being elevated versus optimal risk factor control were 1.09 (95% 
confidence interval, 1.01–1.17) in people with cardio-renal disease but 
1.96 (95% confidence interval, 1.82–2.12) in people without cardio-renal 
disease. People without cardio-renal disease were younger and more likely 
to have suboptimal risk factor control but had fewer prescriptions for risk 
factor modifying medications than those with cardio-renal disease.
CONCLUSIONS: Optimally managed people with T2D have a 21% higher 
CVD risk when compared with controls. People with T2D without cardio-
renal disease would be predicted to benefit greatly from CVD risk factor 
intervention.
© 2020 The Authors. Circulation is 
published on behalf of the American 
Heart Association, Inc., by Wolters 
Kluwer Health, Inc. This is an open 
access article under the terms of the 
Creative Commons Attribution License, 
which permits use, distribution, and 
reproduction in any medium, provided 
that the original work is properly cited.
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Type 2 diabetes (T2D) is a common condition that increases the risk of fatal and nonfatal cardio-vascular disease (CVD).1,2 The Steno-2 trial sug-
gested that in people with T2D, multiple CVD risk fac-
tor intervention might halve the risk of CVD events 
and mortality and may provide up to 8 years longer 
life expectancy3–6.
In observational data of people with T2D and coro-
nary disease, we showed that individuals with subop-
timal risk factor control had a 2-fold higher risk for 
mortality and CVD events when compared with those 
with optimal risk factor control.7 A Swedish population-
based study recently showed similar findings.8 In ad-
dition, it showed: 1) that people with T2D who had 
optimal risk factor control had little or no excess risk 
of death, myocardial infarction, or stroke when com-
pared with the general population; and 2) that rela-
tionships between the degree of risk factor control and 
CVD events were stronger in younger people than older 
people, possibly due to differing baseline CVD risks and 
risk factor management.7
Currently, we don’t know whether people in the 
United Kingdom with T2D who have optimal risk fac-
tor control have similar risks of CVD and mortality to 
people without diabetes, and whether baseline CVD 
risk modifies the relationship between the degree of 
risk factor control and CVD risk. This is important be-
cause quantifying these risks in individuals considered 
to be at low-risk or high-risk for CVD could guide ap-
propriate interventions on CVD risk factors. Therefore, 
in people with T2D, stratified by baseline CVD risk, 
defined by the presence of cardio-renal disease, we 
studied associations between the number of abnormal 
CVD risk factors at baseline with subsequent mortality 
and CVD events, and we compared CVD risk in opti-
mally controlled people with T2D and controls without 
diabetes.
METHODS
Ethical Approval
This study is based in part on data from the CPRD (Clinical 
Practice Research Datalink) obtained under license from the 
UK Medicines and Healthcare products regulatory agency. The 
data are provided by patients and collected by the National 
Health Service (NHS) as part of their care and support. Office 
for National Statistics and Hospital Episode Statistics data are 
subject to Crown copyright (2018) protection, reused with the 
permission of The Health and Social Care Information Centre, 
all rights reserved. The Office of Population Censuses and 
Surveys (OPCS) Classification of Interventions and Procedures, 
codes, terms, and text is Crown copyright (2016) published by 
The Health and Social Care Information Centre, also known as 
NHS Digital and licensed under the Open Government License 
available at www.nationalarchives.gov.uk/doc/open-govern-
ment-license/open-government-license.htm. The study and 
use of CPRD data were approved by the Independent Scientific 
Advisory Committee for CPRD research (ref. 15_123MnA). 
Generation of the anonymised, linked SCI-Diabetes dataset 
(Scottish Care Information-Diabetes) was approved by the 
Scotland multicenter research ethics committee (reference 
11-AL-0225), Caldicott guardians, and the NHS National 
Services Scotland Privacy Application Committee (reference 
33/11). The interpretation and conclusions contained in this 
study are those of the authors alone.
Data Sharing
Read and International Classification of Diseases codes used 
are publicly available at The ClinicalCodes repository and can be 
accessed at https://clinicalcodes.rss.mhs.man.ac.uk/. The pri-
mary care data can be requested via application to the Clinical 
Practice Research Datalink (https://www.cprd.com); secondary 
care data can be requested via application to the hospital epi-
sode statistics from The Health and Social Care Information 
Centre (www.hscic.gov.uk/hesdata); and mortality data are 
available by application to the UK Office for National Statistics 
(www.ons.gov.uk/ons/index.html). Linked SCI-Diabetes data 
can be requested via application to the electronic Data Research 
and Innovation Service (https://www.isdscotland.org/Products- 
and-Services/eDRIS/).
Data Sources
This was a retrospective population-based cohort study using 
data from 2 sources: the Clinical Practice Research Datalink 
(CPRD GOLD), a UK primary care database (only records from 
English practices were included in the study due to linkage 
Clinical Perspective
What Is New? 
• Even when cardiovascular disease (CVD) risk fac-
tors are optimally controlled, people with type 2 
diabetes still have a 21% higher risk of CVD com-
pared with people without diabetes.
• In people with type 2 diabetes without cardio-renal 
disease, there were much stronger relationships 
between the degree of risk control and risks for 
CVD events and mortality than in people with type 
2 diabetes with cardio-renal disease.
• People with type 2 diabetes who had no cardio-
renal disease were younger than people with car-
dio-renal disease and had fewer prescriptions for 
CVD prevention medications.
What Are the Clinical Implications? 
• Overall risk factor management was poor in people 
with type 2 diabetes. Greater use of guideline-
driven care, clinical decision support, drug inter-
vention, and self-management support should be 
encouraged.
• People with type 2 diabetes and without cardio-
renal disease may benefit greatly from CVD risk 
factor intervention.
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restrictions), and the Scottish Care Information-Diabetes sys-
tem (SCI-Diabetes), a Scottish diabetes registry database.
The CPRD is an anonymised, longitudinal primary care 
medical record database of UK general practices.9 In 2015, 
the CPRD GOLD contained data on over 4.4 million active 
(alive, currently registered) patients from 674 registered gen-
eral practices, equating to approximately 6.9% of the UK 
population.9 Patients are broadly representative of the general 
population in terms of age, sex, and ethnicity.9 Approximately 
75% of CPRD GOLD practices are located in England (58% of 
all 674 UK CPRD practices) have consented and participate in 
the CPRD linkage scheme. The CPRD dataset was linked at the 
patient-level to Hospital Episode Statistics, Office for National 
Statistics mortality data, and Index of Multiple Deprivation 
2010, for all eligible patients in 380 English practices.
The SCI-Diabetes dataset, a national diabetes system 
established in 2000, contains data on >99% of all individu-
als diagnosed with diabetes in Scotland.10 SCI-Diabetes is 
a fully integrated shared electronic patient record to sup-
port treatment of National Health Service Scotland patients 
which includes demographics and primary and secondary 
care information relevant to diabetes care.11 In 2015, SCI-
Diabetes contained data on 284 122 people diagnosed with 
diabetes in Scotland (5.3% prevalence) of which 10.7% 
were registered with type 1 diabetes and 88.3% with 
T2D.12 The Information Services Division of NHS National 
Services Scotland linked a 2016 extract of SCI-Diabetes data 
to national mortality records and hospital data from the 
Scottish Morbidity Records (SMR01).
Study Populations
Figure 1 outlines the study populations included at each ana-
lytic phase.
CPRD
T2D cases were identified from Read codes (coded thesau-
rus of clinical terms used in primary care13) in the electronic 
record between January 1, 2006, and December 31, 2013. 
A validated algorithm classified people with T2D based on 
diabetes codes available, diabetes treatments, age, body mass 
index, and ethnicity as described previously.1,14 The index date 
in the T2D cohort was defined as the first diagnostic code 
or diabetes treatment within the study window. Incident T2D 
was defined if there was no history of diagnostic codes for 
diabetes or diabetes treatments prior to the index date.
People with T2D were matched with up to 5 controls 
without diabetes (any type) on year of birth (± 2 years), sex, 
general practice, and index date. For cohort entry, individu-
als with T2D and controls without diabetes were required to 
have at least 1 year prior registration at their current prac-
tice and for the practice to be up-to-standard for research 
purposes (a CPRD practice-based quality metric based on 
continuity and accuracy of data recording). All participants 
were observed from the index date to the end point date; 
the study end date (March 31, 2015), the practice’s last 
data collection date, death, or transfer out of practice, 
whichever occurred first.
SCI-Diabetes
People with T2D were identified from a 2016 extract of the 
SCI-Diabetes database in which diabetes type is recorded by 
a clinician at diagnosis. For research purposes, an algorithm 
based on age at diagnosis, use, and timing of treatment with 
oral hypoglycaemics and insulin is applied to validate type of 
diabetes.15 The entry date to the cohort was January 1, 2006, 
for people with prevalent T2D and the date of T2D diag-
nosis for those diagnosed after that date. Participants were 
observed from cohort entry to the earliest outcome date, 
death, or the study end date (March 31, 2015).
Cardiovascular Outcomes
In both datasets, information on cardiovascular outcomes was 
identified from hospital records (Hospital Episode Statistics 
in England and SMR01 in Scotland), detailed in Figure I in 
the Data Supplement, and death records (Office for National 
Statistics in England and national death registrations in 
Scotland) using the following ICD-10 codes: coronary heart 
disease (I20-I25), stroke (I60-I64), hospitalisation for heart 
failure (I50), and other forms of heart disease (I30-I52).
Primary study outcome included a composite of total CVD 
events (fatal/nonfatal coronary heart disease (CHD), stroke, 
or heart failure hospitalisation). Secondary outcomes included 
nonfatal CHD, nonfatal stroke, nonfatal heart failure, total 
CVD mortality, fatal CHD, and fatal stroke.
Patient Demographics and Baseline 
Clinical Characteristics
In CPRD, ethnicity was identified from the primary care records 
using Read codes and through Hospital Episode Statistics 
linkage as described previously.1 In SCI-Diabetes, ethnicity is 
self-assigned by the person with diabetes using the ethnic 
groups list from the 2001 Scottish Census.15 In CPRD and 
SCI-Diabetes, ethnicity was categorized into 4 groups: White, 
South Asian, Black, and Other. Deprivation data were defined 
using the Index of Multiple Deprivation 2010 classification in 
CPRD and the Scottish Index of Multiple Deprivation in SCI-
Diabetes both categorized into 5 quintiles: 1 (most deprived) 
to 5 (least deprived).
In CPRD, history of CVD at baseline was defined using 
Read codes and ICD-10/OPCS-4 (OPCS Classification of 
Interventions and Procedures version 4; NHS coding for inter-
ventions and surgical procedures16) codes before the index 
date for the following cardiovascular conditions: myocardial 
infarction, stroke, heart failure, CHD, cerebrovascular disease, 
peripheral vascular disease, and revascularisation interven-
tions. For the SCI-Diabetes cohort, prevalent CVD was defined 
based on ICD-10/OPCS-4 (Office of Population Censuses and 
Surveys [OPCS] Classification of Interventions and Procedures 
version 4) codes alone.
For both CPRD and SCI-Diabetes, moderate to severe 
renal impairment that is likely to affect treatment decisions 
was defined using eGFR values <45 mL/min/1.73m2. Risk 
factors (smoking, body mass index, total cholesterol, triglyc-
erides, glycated haemoglobin [HbA1c], and blood pressure) 
were identified from the closest recording up to 1 year before 
or after the index date. Drug prescriptions for antidiabetics, 
antihypertensives, lipid-lowering therapies, and antiplatelet 
agents were defined in the period up to 3 months prior to 
index date.
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Figure 1. Study populations from CPRD (Clinical Practice Research Datalink) and SCI-Diabetes (Scottish Care Information-Diabetes) at each analytic 
phase.
ADMs indicates antidiabetic medications; BMI, body mass index; CVD, cardiovascular disease; and T2D, type 2 diabetes.
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Definition of Risk Factor Control
In CPRD and SCI-Diabetes, individuals with T2D were cat-
egorized into 6 groups, defined by the number of baseline 
risk factors above clinically optimal levels (ranging from 0–5). 
Based on the National Institute for Health and Care Excellence 
guidance (evidence-based recommendations for health and 
care in the United Kingdom), we used the following risk fac-
tor thresholds to define suboptimal status among people with 
T2D: current smoker, total cholesterol >4 mmol/L, triglycer-
ides >1.7 mmol/L, HbA1c (glycohemoglobin) ≥53 mmol/mol 
(7.0%), and systolic blood pressure >140 mm Hg or >130 
mm Hg in the presence of renal impairment, retinopathy or 
cerebrovascular disease.17
Statistical Analysis
Age-standardized incidence rates, using the European 
Standard Population (unweighted average of individual popu-
lations from all 27 European Union countries and 3 European 
Free Trade Association States),18 expressed per 100 person-
years, were calculated for cardiovascular outcomes in controls 
and in people with T2D stratified by the number of risk fac-
tors above target levels and by presence/absence of cardio-
renal disease (defined as prior myocardial infarction, stroke, 
CHD, or eGFR <45 mL/min/1.73m2).
In CPRD, we used Cox regression to examine risks for pri-
mary and secondary outcomes in relation to the number of risk 
factors above threshold values among people with T2D com-
pared with matched controls. In CPRD and SCI-Diabetes T2D 
cohorts, Cox regression examined risks for CVD outcome asso-
ciated with the number of risk factors above threshold values 
compared with people with optimal risk factor control (ie, no 
risk factors above threshold values). Cox models were adjusted 
for age, sex, deprivation, ethnicity, diabetes duration, and his-
tory of CVD. To account for matched cohort design, the Cox 
regression was stratified by matched sets. History of CVD was 
not included in the analyses stratified by cardio-renal disease. 
Risk estimates from the 2 cohorts were pooled by DerSimonian 
and Laird random-effects meta-analysis. A P value <0.05 was 
considered statistically significant. The Bonferroni adjustment 
was applied to the analysis of secondary end points, computing 
confidence intervals (CIs) and P values that account for multiple 
comparisons. As a sensitivity analysis, models were stratified 
by gender to assess for effect modification in the relationship 
between risk factor control and CVD outcomes.
Missing baseline data were imputed with the multivariate 
imputation by chained equations algorithm. Five complete 
data sets were imputed; variables used in imputation are pro-
vided in Methods in the Data Supplement.
All relevant code lists for variables and outcomes are pub-
licly available at The ClinicalCodes repository19 and can be 
accessed at https://clinicalcodes.rss.mhs.ac.uk. Analyses were 
performed using Stata 15.1 (StataCorp LP, College Station, TX).
RESULTS
Study Populations
Baseline characteristics of the study cohorts are shown 
in the Table, with additional detail provided in Table 
I in the Data Supplement (CPRD) and Table II in the 
Data Supplement (SCI-Diabetes). The CPRD cohort 
comprised of 101 749 people with T2D and 378 938 
controls without diabetes with median (interquartile 
range) follow-up of 2.9 (1.3–5.3) years and 3.0 (1.3–
5.4) years, respectively. A total of 73 096 (72%) people 
with T2D had complete data on all 5 risk factors and 
68 815 (94%) individuals had at least 1 risk factor at a 
suboptimal level. The SCI-Diabetes cohort comprised of 
330 892 individuals with T2D with a median (interquar-
tile range) follow-up of 6.4 (3.1–9.2) years. A total of 
201 653 (61%) people had complete data on all 5 risk 
factors and 189 404 (94%) individuals had at least 1 
risk factor at a suboptimal level.
Clinical characteristics of the 2 cohorts were broadly 
similar. Compared with T2D patients in SCI-Diabetes, 
T2D patients in CPRD were slightly older, less likely to 
be current smokers, and less likely to have CVD and 
renal impairment, but had higher body mass index, to-
tal cholesterol, and HbA1c levels. Prescribing of antidia-
betic, lipid-lowering, and antiplatelet medication were 
Table 1. Baseline Clinical Characteristics of People With T2D From 
Scotland and of People With T2D and Controls From England
 
Type 2 diabetes Controls
SCI-Diabetes CPRD CPRD
n 330 892 101 749 378 938
Mean (SD) age, y 61.9±13.2 63.3±14.3 64.7±14.4
Women, n (%) 148 355 (45) 46 569 (46) 185 790 (49)
Incident diabetes 
during FU, n (%)
162 847 (49) 73 214 (72) –
Mean (SD) diabetes 
duration, y
6.4 (6) 5.3 (16) –
Mean (SD) BMI, kg/
m2
31.6±6.3 32.0±7.0 27.4±5.6
CVD, n (%) 97 170 (29) 27 378 (27) 71 165 (19)
Renal impairment, 
n (%)
43 805 (13) 10 123 (10) 31 130 (8.2)
Current smoking, 
n (%)
67 680 (20) 19 270 (19) 61 344 (17)
Raised total 
cholesterol, n (%)
222 667 (67) 68 984 (68) 158 041 (42)
Raised triglycerides, 
n (%)
122 173 (37) 43 134 (42) 44 697 (12)
Raised HbA1c, n (%) 173 519 (52) 49 867 (49) 214 (0.1)
Raised blood 
pressure, n (%)
66 843 (20) 21 472 (21) 58 475 (15)
CVD was defined as a history of myocardial infarction, stroke, heart failure, 
coronary heart disease, cerebrovascular disease, peripheral vascular disease, 
and revascularization interventions. Renal impairment was defined as an 
eGFR<45 mL/min/1.73m2. Abnormal risk factor status was defined as current 
smoker, total cholesterol >4 mmol/L, triglycerides >1.7 mmol/L, HbA1c  ≥53 
mmol/mol (7.0%), and blood pressure >140/80 mm Hg or >130/80 mm Hg in 
the presence of renal impairment, retinopathy, or cerebrovascular disease BMI 
indicates body mass index; CPRD, Clinical Practice Research Datalink (England); 
CVD, cardiovascular disease; FU, follow-up; HbA1c, glycated haemoglobin; 
SCI-Diabetes, Scottish Care Information-Diabetes (Scotland); SD, standard 
deviation; and T2D, type 2 diabetes. 
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all lower in CPRD. Forty percent of participants were re-
ceiving glucose lowering medication reflecting the high 
proportion with newly diagnosed T2D (72%, CPRD; 
49%, SCI-Diabetes). In both study cohorts, younger age 
was associated with a higher number of suboptimal risk 
factors present (Table I in the Data Supplement [CPRD] 
and Table II in the Data Supplement [SCI-Diabetes]).
Prevalent cardio-renal disease was identified in 
28 933 (28%) people with type 2 diabetes in CPRD 
and 115 342 (35%) in SCI-Diabetes. Across CPRD and 
SCI-Diabetes, people with T2D and without prevalent 
cardio-renal disease (defined as at low risk of CVD) 
were on average 11 years younger than people with 
prevalent cardio-renal disease (mean age 58.9±13.2 
versus 70.5±11.4 years) and were more likely to have a 
greater number of risk factors at suboptimal levels and 
fewer prescriptions for lipid-lowering medications, an-
tiplatelet agents, and antihypertensive agents (Table III 
in the Data Supplement [CPRD] and Table IV in the Data 
Supplement [SCI-Diabetes]).
Incidence Rates for Cardiovascular Events 
and Mortality
During the study period, cardiovascular events occurred 
in 27 900 (27%) patients with T2D in CPRD, 72 520 
(19%) controls in CPRD, and in 101 362 (31%) pa-
tients with T2D in SCI-Diabetes. Cardiovascular death 
occurred in 3144 (3.1%) patients with T2D in CPRD, 
10 131 (2.7%) controls in CPRD, and in 26 974 (8.1%) 
patients with T2D in SCI-Diabetes.
Age-standardized incidence rates for the cohorts are 
shown in Table V in the Data Supplement. In people 
with T2D with complete data on all 5 risk factors, the 
incidence of CVD events was generally higher in SCI-
Diabetes compared with CPRD across all risk factor 
control levels, with the exception of heart failure hospi-
talization. A U-shaped relationship between degree of 
risk factor control and CVD incidence was observed in 
both cohorts when previous CVD history was not taken 
into account. Cardiovascular mortality was consistently 
higher in SCI-Diabetes.
Incidence rates were considerably higher in those 
with prevalent cardio-renal disease compared with 
those without cardio-renal disease (Table VI in the Data 
Supplement).
Risk for Cardiovascular Events and 
Mortality
Figure  2 shows the adjusted hazard ratios (HRs) for 
cardiovascular outcomes associated with the number 
of risk factors above threshold values in CPRD T2D pa-
tients compared with controls without diabetes. Over-
all, people with T2D had an approximately 30% higher 
risk of cardiovascular events compared with controls 
after adjusting for age, sex, deprivation, ethnicity, and 
prevalent CVD.
Across all cardiovascular events, increasing numbers 
of risk factors above thresholds were associated with 
higher adjusted risks relative to controls. For people with 
T2D who had optimal risk factor control, the adjusted 
HR for CVD events was 1.21 (95% CI, 1.12–1.29) com-
pared with controls. The corresponding adjusted HR 
was 2.15 (95% CI, 1.83–2.53) for those with all 5 risk 
factors above target levels. Cardiovascular mortality risk 
among people with T2D and 0 to 2 risk factors above 
targets was not significantly higher than controls. As 
the number of risk factors above target levels increased 
(3–5 risk factors), the risk for cardiovascular death in-
creased and was significantly higher than controls.
Overall, compared to optimally controlled people 
with T2D in CPRD and SCI-Diabetes, those with T2D 
and 5 risk factors above target had pooled adjusted HRs 
of 1.40 (95% CI, 1.33–1.47) for total CVD events, 1.25 
(95% CI, 1.18–1.32) for nonfatal CHD, 2.30 (95% CI, 
2.02–2.63) for nonfatal stroke, 1.46 (95% CI, 1.31–
1.63) for heart failure hospitalization, 1.73 (95% CI, 
1.54–1.95) for total CVD morality, 1.84 (95% CI, 1.60–
2.11) for CHD mortality, and 1.80 (95% CI, 1.33–2.43) 
for stroke mortality (Figure 3 [total CVD] and Figure II 
in the Data Supplement [individual CVD components]).
In people with T2D and cardio-renal disease, the 
pooled association between the number of risk factors 
above target and risk of CVD events was weak (Fig-
ure 4A). There was no significant risk increase when 1 to 
3 risk factors were above thresholds; however, when 4 
and 5 risk factors were elevated, the respective risks were 
7% (HR, 1.07; 95% CI, 1.03–1.11) and 9% (HR, 1.09; 
95% CI, 1.01–1.17) higher than optimally controlled 
people. In contrast, in people with T2D and no cardio-
renal disease, CVD risk increased stepwise for each ad-
ditional risk factor above target, with a near 2-fold (HR, 
1.96; 95% CI, 1.82–2.12) higher risk for those with 5 
elevated risk factors (Figure 4A). A similar pattern was 
observed for CVD mortality with stronger associations 
with risk factor control in those without cardio-renal dis-
ease (Figure 4B). In people with T2D and cardio-renal 
disease, CVD mortality risk was modestly higher than 
in optimally controlled patients when 4 (HR, 1.31; 95% 
CI, 1.22–1.39) or 5 (HR, 1.52; 95% CI, 1.28–1.80) risk 
factors were above targets. However, in contrast, those 
without cardio-renal disease with 1 risk factor above tar-
get had a 16% (HR, 1.16; 95% CI, 1.04–1.29) higher 
CVD mortality risk compared with optimally controlled 
people. Each additional risk factor above target was as-
sociated with increasingly higher risks, with more than 
twice the risk observed in those with 5 risk factors above 
target (HR, 2.27; 95% CI, 1.85–2.79). A similar pattern 
was observed for the risks for individual nonfatal and fa-
tal events (CHD, stroke, and heart failure hospitalization) 
associated with different levels of risk factor control in 
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patients with and without cardio-renal disease (Figure 
IIIA in the Data Supplement [CVD events] and Figure IIIB 
in the Data Supplement [CVD mortality]).
In the sensitivity analysis, stratifying by gender had 
no material effect on the relationship between the de-
gree of risk factor control and risk of CVD outcomes 
(results not shown).
DISCUSSION
Key Findings
Our key findings with important clinical implications 
are: 1) compared with people without diabetes, those 
with T2D and optimally managed risk factors have a 
21% higher risk for all CVD events and nonfatal CHD 
and a 31% higher risk for heart failure hospitalization; 
2) only 6% of people with T2D had optimal risk fac-
tor control; and 3) the association between the number 
of elevated risk factors and CVD events/mortality was 
much stronger in people with T2D without cardio-renal 
disease when compared with T2D and established car-
dio-renal disease.
Prior Studies
The landmark Steno-2 trial showed that intensive CVD 
risk factor intervention could halve risk for both CVD 
events and mortality in subjects with T2D and microal-
buminuria.3–6,20 In an extended follow-up of the cohort, 
life expectancy was 8 years longer with intensive risk 
factor control.5 These impressive results show how si-
multaneous intervention on multiple risk factors might 
have major benefits in people with T2D. However, the 
optimal strategy for multifactorial intervention in T2D 
has not been established based on other multifactorial 
intervention trials,21–24 and meta-analyses,25 that have 
provided inconsistent results. It is useful to highlight 
that these trials were performed before SGLT2 inhibi-
tors (SGLT2i) and GLP-1 receptor agonists (GLP-1RA) 
were in common clinical use. Since these agents im-
prove CVD risk factors,26–28 and reduce CVD risk, inten-
sive intervention using these agents may deliver even 
more impressive CVD benefits than the Steno-2 trial 
might suggest.29,30
Our observational data suggest that in people with 
T2D there is a clinically significant residual CVD risk even 
when all causal risk factors are optimally managed, at 
least to levels mandated in the United Kingdom by the 
National Institute for Health and Care Excellence 17; 
21% to 31% higher risk for CVD events and heart fail-
ure hospitalization compared with people without dia-
betes. These findings are in contrast to the results from 
a large T2D Swedish study in which optimal risk factor 
control was not linked to higher risks when compared 
Figure 2. Multivariable-adjusted relative hazards for cardiovascular disease (CVD) events (fatal or nonfatal CVD event or heart failure hospitaliza-
tion) and mortality according to number of risk factors above thresholds in people with type 2 diabetes (CPRD [Clinical Practice Research Datalink]) 
compared to matched controls without diabetes (CPRD).
Adjusted for age, sex, deprivation, ethnicity, diabetes duration and history of CVD. Hazard ratios are pooled from all 5 data sets. Number of events and population 
represent the mean in the 5 data sets. CHD indicates coronary heart disease; CI, confidence interval; DM, diabetes; HF, heart failure; and HR, hazard ratio.
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with the general population.8 Potential explanations for 
these discrepant results include: 1) differences in the 
risk factors studied, specifically regarding albuminuria 
and cholesterol; 2) differences in the health of partici-
pants without diabetes; and 3) differences in diabetes 
management including lifestyle interventions and type 
of diabetes medications.
As far as we are aware, no diabetes study has pre-
viously shown that the associations between risk fac-
tor levels and CVD outcomes were stronger in low-risk 
people without cardio-renal disease compared with 
high-risk individuals with cardio-renal disease. These 
findings have important clinical implications. Individu-
als with T2D and absence of cardio-renal disease were 
younger than T2D individuals with cardio-renal disease 
(mean age: 59 versus 71 years) and had higher CVD risk 
factors levels. The risk difference between the least and 
best-controlled low-risk individuals was ≈2-fold higher 
for both CVD events and for CVD mortality (Figure 4), 
suggesting the importance of optimal medical therapy 
in these people. This follows a similar pattern observed 
in data presented by Rawshani et al in which risks for 
death and cardiovascular outcomes increased dramati-
cally in younger than in older people.8 These more pro-
nounced risks in younger individuals without cardio-
renal disease may be due to the age at which T2D was 
diagnosed. Younger-onset T2D poses greater excess 
CVD morbidity and mortality risk than later-onset T2D, 
highlighting the need for, and the potential gains from, 
more aggressive intervention.31
We can only speculate on the reasons why asso-
ciations between risk factor levels and CVD outcomes 
were stronger in people without cardio-renal disease. 
Although differences in drug regimens and drug in-
teractions may play a role, it seems plausible that dif-
ferent metabolic pathways could underlie the devel-
opment and progression of intimal plaque atheroma 
seen in people without cardio-renal disease compared 
with the medial arterial calcification commonly seen 
in those with cardio-renal disease. Our data, and the 
disappointing results of clinical trials of CVD risk factor 
intervention in dialysis populations, support the idea 
that risk factor intervention needs to be initiated early, 
before CVD or stage 3b chronic kidney disease devel-
ops, in order to maximize the benefits of risk reduction 
by these means.32
We showed that in individuals with cardio-renal dis-
ease, risk factor levels appeared to contribute little to 
the relative risk for the combined fatal and nonfatal 
CVD event end point (9% relative risk between opti-
mally-controlled and poorly controlled participants) but 
were strongly related to risk for fatal CVD (52% relative 
risk). Therefore, benefits from risk factor intervention in 
this group may be dominated by a reduction in risk for 
fatal CVD rather than nonfatal CVD.
Clinical Implications
While the benefits of optimal risk factor control have 
been demonstrated (risk differences between the 
Figure 3. Meta-analysis of multivariable-adjusted relative hazards for cardiovascular disease (CVD) events (fatal or nonfatal CVD event or heart fail-
ure hospitalization) and mortality according to number of risk factors above thresholds in people with type 2 diabetes from CPRD (Clinical Practice 
Research Datalink) and SCI-Diabetes (Scottish Care Information-Diabetes) compared to optimally controlled type 2 diabetes.
Adjusted for age, sex, deprivation, ethnicity, diabetes duration, and history of CVD. Hazard ratios are pooled from all 5 data sets. Number of events and population 
represent the mean in the 5 data sets. CI indicates confidence interval; and HR, hazard ratio.
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best- and least-controlled individuals with T2D was 
40% for CVD events and 73% for CVD mortality) we 
observed that only 6% of people with T2D had optimal 
risk factor control. The issue of inadequate risk factor 
management in T2D is an international problem.33–35
Our data supports early and more intensive interven-
tion in people with T2D who are perceived to be at low-
er risk (without established cardio-renal disease), whom 
on average, have higher body mass index, total choles-
terol, HbA1c, and blood pressure levels than individuals 
Figure 4. Meta-analysis of multivariable-adjusted relative hazards for cardiovascular disease (CVD) events.
A, fatal or nonfatal CVD event or heart failure hospitalisation and (B), CVD mortality, according to number of risk factors above thresholds in people with type 2 
diabetes from CPRD (Clinical Practice Research Datalink) and SCI-Diabetes (Scottish Care Information-Diabetes) compared with optimally controlled type 2 diabe-
tes, stratified by the presence of cardio-renal disease. Cardio-renal disease defined as: prior history of acute myocardial infarction, stroke, coronary heart disease 
and/or renal impairment. Adjusted for age, sex, deprivation, ethnicity, and diabetes duration. Hazard ratios are pooled from all 5 data sets. Number of events and 
population represent the mean in the 5 data sets. CI indicates confidence interval; HR, hazard ratio; and T2D, type 2 diabetes. 
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with established cardio-renal disease. Such intervention 
could yield substantial long-term reductions in CVD 
events and mortality at the population level. In keep-
ing with the results of the National Diabetes Audit,35 
our data showed that a smaller proportion of patients 
without cardio-renal disease were receiving antihyper-
tensive therapy and statins compared with people with 
cardio-renal disease (48% versus 80% and 37% versus 
70%, respectively). We support calls for greater use of 
early guideline-driven care, wider use of newer agents 
including SGLT2i and GLP-1RA that lower cardio-renal 
risks beyond effects on HbA1c, pharmacist-led clinics,36 
IT systems supporting self-management,37 and clinical 
decision support for clinical staff.38
While we emphasise the potential benefits of risk 
factor reduction in individuals without cardio-renal 
disease (considered to be low-risk), we would not 
want to minimize the potential importance of risk 
factor control in patients with cardio-renal disease 
(considered to be high-risk) for several reasons: 1) our 
data do not inform us about the potential benefits of 
treatment already given to individuals considered to 
be at high-risk (eg, ≈3 quarters were receiving anti-
hypertensive and lipid-lowering therapy); 2) although 
our data predict modest further reductions in the 
relative risk for total CVD in people with cardio-renal 
disease through further risk factor intervention, the 
number needed to treat to prevent an event may be 
small due to high absolute risk for events; and 3) risk 
factors studied appeared to contribute significantly to 
the relative risk for fatal CVD events (52% relative risk 
between optimally controlled and poorly controlled 
participants).
Strengths and Limitations
Our study strengths include: 1) combining linked data 
from 2 large T2D cohorts from England and Scotland; 
2) having a control group without diabetes; 3) stratify-
ing outcomes by baseline CVD risk, defined by preva-
lent cardio-renal disease; and 4) presenting results 
which are general to the UK population. We acknowl-
edge these limitations: omission of albuminuria as a 
risk factor due to lack of data, and in CPRD, prevalent 
T2D cases were required to have a diabetes diagnostic 
code documented by the General Practice within the 
study window period (2006–2013). Since such coding 
may occur sometimes after hospitalization, these cases 
may have higher CVD risk than prevalent cases not sat-
isfying this selection criterion. However, this limitation 
is unlikely to have substantially affected our results as 
the proportion of prevalent T2D in CPRD was 28%, 
and as shown, relationships between risk factor levels 
and CVD risk were similar between our CPRD and SCI-
Diabetes cohorts, with the latter capturing the entire 
population in Scotland.
CONCLUSIONS
Compared with people without diabetes, those with 
T2D have higher risks for CVD events, CVD mortality, 
and heart failure hospitalization even when all causal 
risk factors are optimally controlled to levels mandated 
in current clinical guidelines. We found that the asso-
ciation between risk factor levels and CVD outcomes 
was much stronger in people with T2D without cardio-
renal disease when compared with those with cardio-
renal disease at cohort entry. Since overall risk factor 
management was poor, we encourage greater use of 
guideline-driven care, newer agents including SGLT2i 
and GLP-1RA, pharmacist-led clinics, IT systems sup-
porting self-management, and clinical decision to sup-
port for clinical staff.
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